{"id":"bt061","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This can help to reduce the number of cancer cells in the body.","oneSentence":"BT061 is a monoclonal antibody targeting CD19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:17:35.615Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT01999192","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biotest","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":321},{"nctId":"NCT01481493","phase":"PHASE2","title":"Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)","status":"COMPLETED","sponsor":"Biotest","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":127},{"nctId":"NCT01072383","phase":"PHASE2","title":"Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Biotest","startDate":"2010-02","conditions":"Psoriasis Vulgaris","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["immune-modulatory antibody BT061","SC or IV administration of BT061 or placebo"],"phase":"phase_2","status":"active","brandName":"BT061","genericName":"BT061","companyName":"Biotest","companyId":"biotest","modality":"Biologic","firstApprovalDate":"","aiSummary":"BT061 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}